OUR MISSION
We aspire to develop a completely in situ platform drug technology optimized for solid tumor cancers that achieves CAR-T like efficacy demonstrated in liquid tumors
EXECUTIVE LEADERSHIP
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARD
JON CONDRA, PH.D.
- Merck Research Laboratories (retired)
- Former Associate Professor, Temple University School of Pharmacy
ALAN EPSTEIN, PH.D.
- University of Southern California
- Professor, Keck School of Medicine
RICHARD HARRIS, M.D.
- CEO of UroPartners
- President of Large Urology Group Practice Association (LUGPA) BOD
JOHN MORRIS, M.D.
- Director, Experimental Therapeutics at Cincinnati College of Medicine
- Co-Director, Comprehensive Lung Cancer Center
- Associate Director, UCCI Translational Research
GEORGE C. PRENDERGAST, PH.D.
- President and CEO of the Lankenau Institute for Medical Research (LIMR)
- Former Editor-in-Chief of Cancer Research
THOMAS RAFFIN, M.D.
- Stanford University School of Medicine Colleen and Robert Haas Professor Emeritus of Medicine and Biomedical Ethics
- Former Chief of Pulmonary and Critical Care Medicine
DAVID STARK, M.D.
- Former Chairman of the Department of Radiology, State University of New York, Downstate Medical Center
KENNETH THOMSON, M.D.
- Former Adjunct Professor and Director of Radiology, Alfred Hospital
- Former Deputy Director of Radiology and Head of Interventional Radiology, The Royal Melbourne Hospital
DAVID VAUGHAN, M.D.
- Former Chairman of Department of Urology at Florida Hospital & Winter Park Hospital
- Former Partner of Orlando Urology Associates
SUMING WANG, M.D., PH.D.
JASON WILLIAMS, M.D.
- Chief of Interventional Oncology and Immunotherapy, Williams Cancer Institute
- Adjunct Associate Professor, Case Western Reserve University
- Author “The Immunotherapy Revolution”
YOUSEF ZAKHARIA, M.D.
- Clinical Associate Professor of Medicine, University of Iowa
- Director Phase I Program, Co-Leader Genitourinary Oncology Program, University of Iowa
